AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca net intangible assets carrying value ($M) ($M)
Form 20-F Note 10/11 — Intangible Assets & Individual Medicine Carrying Values
Latest, Q2 2026
37,723
Period ended Jun 30, 2026
Change on a year earlier
-0.5%
37,925 in Q2 2025
History
21 quarters
Since Q4 2015
Sources
17
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Net intangible assets carrying value ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 37,723 | -0.5% | Form 6-K (filed 2026-07-27) ↗ |
| Q4 2025 | Dec 31, 2025 | 37,846 | +1.8% | Form 20-F (filed 2026-02-24) ↗ |
| Q2 2025 | Jun 30, 2025 | 37,925 | -3.8% | Form 6-K (filed 2025-07-29) ↗ |
| Q4 2024 | Dec 31, 2024 | 37,177 | -2.4% | Form 20-F (filed 2025-02-18) ↗ |
| Q2 2024 | Jun 30, 2024 | 39,426 | +2.9% | Form 6-K (filed 2024-07-25) ↗ |
| Q4 2023 | Dec 31, 2023 | 38,089 | -3.1% | Form 20-F (filed 2024-02-20) ↗ |
| Q2 2023 | Jun 30, 2023 | 38,326 | -3.9% | Form 6-K (filed 2023-07-28) ↗ |
| Q4 2022 | Dec 31, 2022 | 39,307 | -7.5% | Form 20-F (filed 2023-02-21) ↗ |
| Q2 2022 | Jun 30, 2022 | 39,900 | +99.4% | Form 6-K (filed 2022-07-29) ↗ |
| Q4 2021 | Dec 31, 2021 | 42,492 | +102.9% | Form 20-F (filed 2023-02-21) ↗ |
| Q2 2021 | Jun 30, 2021 | 20,006 | +1.4% | Form 6-K (filed 2021-07-30) ↗ |
| Q4 2020 | Dec 31, 2020 | 20,947 | +0.5% | Form 20-F (filed 2021-02-16) ↗ |
| Q2 2020 | Jun 30, 2020 | 19,728 | -11.4% | Form 6-K/A (filed 2020-07-31) ↗ |
| Q4 2019 | Dec 31, 2019 | 20,833 | -5.1% | Form 20-F (filed 2020-03-03) ↗ |
| Q2 2019 | Jun 30, 2019 | 22,257 | -10.6% | Form 6-K (filed 2019-07-25) ↗ |
| Q4 2018 | Dec 31, 2018 | 21,959 | -16.1% | Form 20-F (filed 2019-03-05) ↗ |
| Q2 2018 | Jun 30, 2018 | 24,887 | -9.4% | Form 6-K (filed 2018-07-26) ↗ |
| Q4 2017 | Dec 31, 2017 | 26,188 | -5.1% | Form 20-F (filed 2018-03-06) ↗ |
| Q2 2017 | Jun 30, 2017 | 27,465 | – | Form 6-K (filed 2018-07-26) ↗ |
| Q4 2016 | Dec 31, 2016 | 27,586 | +21.8% | Form 20-F (filed 2018-03-06) ↗ |
| Q4 2015 | Dec 31, 2015 | 22,646 | – | Form 20-F (filed 2018-03-06) ↗ |
Breakdown
What makes up net intangible assets carrying value ($m)
- Product, marketing & distribution rights — net carrying value ($M)–
- Software & IT intangibles — net carrying value ($M)–
- Other intangible assets & IPR&D — net carrying value ($M)–
- Gross intangible assets cost ($M)–
- Accumulated amortisation & impairment of intangible assets ($M)–
- Medicine intangible — C5 franchise: Soliris & Ultomiris (Alexion) ($M)–
- Medicine intangible — Strensiq & Kanuma (Alexion) ($M)–
- Medicine intangible — Alexion launched & IPR&D pipeline assets ($M)–
- Medicine intangible — Calquence (Acerta Pharma) ($M)–
- Medicine intangible — Enhertu (Daiichi Sankyo alliance) ($M)–
- Medicine intangible — Datroway (Daiichi Sankyo alliance) ($M)–
- Medicine intangible — Baxdrostat (CinCor Pharma acquisition) ($M)–
- Medicine intangible — Lokelma (ZS Pharma) ($M)–
- Medicine intangible — Fusion Pharmaceuticals radioconjugates ($M)–
- Medicine intangible — Gracell Biotechnologies CAR-T ($M)–
- Medicine intangible — Amolyt Pharma (eneboparatide) ($M)–
- Medicine intangible — Airsupra (Bond Avillion) ($M)–
- Intangible amortisation charged to R&D expense ($M)–
- Intangible amortisation charged to SG&A expense ($M)–
Cite this data
StockData. (2026). AstraZeneca Net intangible assets carrying value ($M) ($M), quarterly Q4 2015–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/intang_net_total
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.